The Complement System

Szebeni, János

doi:10.1007/b110959

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2005

2024

Publication Types

Select...

Article3

Other2

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 13 publications

References 126 publications

(518 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View

Szebeni

2016

Nanoscience and Nanotechnology for Human Health

View full text Add to dashboard Cite

Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View

Szebeni

2016

Nanoscience and Nanotechnology for Human Health

View full text Add to dashboard Cite

Perfluorocarbon-based artificial oxygen carriers for red blood cell substitutes: considerations and direction of technology

Kim,

Jung,

Kim

2024

J. Pharm. Investig.

View full text Add to dashboard Cite

Background Recently, the development of an artificial oxygen carrier that can replace blood transfusions is gaining attention, particularly in response to war and the COVID-19 pandemic. However, as yet, none of the existing hemoglobin-based artificial oxygen carriers (HBOCs) and perfluorocarbon-based artificial oxygen carriers (PFOCs) have been approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Area covered Several difficulties are encountered during the development of PFOCs. Here, we discuss the possibility of developing PFOCs using a safe and feasible method. The problems of the existing PFOCs were primarily identified as their large particle size, persistence in the body, and high content of PFOCs based on the second generation. On the basis of these problems, we present the unmet needs of five existing PFOCs that require to be overcome before they can be developed clinically. Expert opinion In previous studies, there have been mentions of the composition, indications, and side effects of PFOCs (Perfluorocarbon-based oxygen carriers). However, there has been little or no mention of unmet needs for the development of PFOCs. Furthermore, this review provides a categorized list of unmet needs for PFOCs, which is expected to contribute to increasing the development potential of PFOCs by providing guidance for future directions.

show abstract

C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis

Qi¹,

Tüzün²,

Allman³

et al. 2008

Journal of Neuroimmunology

View full text Add to dashboard Cite

C5 deficient mice are highly resistant to experimental autoimmune myasthenia gravis (EAMG) despite intact immune response to acethylcholine receptor (AChR), validating the pivotal role played by membrane attack complex (MAC, C5b-9) in neuromuscular junction destruction. To distinguish the significance of C5a from that of C5b in EAMG pathogenesis, C5a receptor (C5aR) knockout (KO) and wild-type (WT) mice were immunized with AChR to induce pathogenic antiAChR antibodies. In contrast with C5 deficient mice, C5aR KO mice were equally susceptible to EAMG as WT mice and exhibited comparable antibody and lymphocyte proliferation response to AChR implicating that C5a is not involved in EAMG development.

show abstract

The Complement System

Cited by 13 publications

References 126 publications

Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View

Challenges and Risks of Nanotechnology in Medicine: An Immunologist's Point of View

Perfluorocarbon-based artificial oxygen carriers for red blood cell substitutes: considerations and direction of technology

C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis

Contact Info

Product

Resources

About